tobramycin has been researched along with Lung Diseases in 59 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 23 (38.98) | 18.7374 |
| 1990's | 8 (13.56) | 18.2507 |
| 2000's | 17 (28.81) | 29.6817 |
| 2010's | 11 (18.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dudley, MN; Griffith, DC; Miller, CE; Nolan, TG; Sabet, M; Senekeo-Effenberger, K | 1 |
| Burns, JL; Dudley, MN; Griffith, DC; King, P; Lomovskaya, O | 1 |
| Amighi, K; Pilcer, G; Rosière, R; Sebti, T; Traina, K; Vanderbist, F | 1 |
| Cantón, R; Girón, RM; Lamas, A; Máiz, L; Mensa, J; Olveira, C; Pastor, D; Quintana, E | 1 |
| Amighi, K; De Bueger, V; Pilcer, G; Sebti, T; Traina, K; Traore, H; Vanderbist, F | 1 |
| Alipour, M; Lui, EM; Omri, A; Suntres, ZE | 1 |
| Malcolmson, RJ; Miller, DP; Nakamura, J; Tan, T; Tarara, TE; Weers, JG | 1 |
| Bielecki, P; Gocht, B; Häussler, S; Kasnitz, N; Komor, U; Moter, A; Pawar, V; Pils, MC; Rohde, M; Weiss, S | 1 |
| Biondo, L; Brigg Turner, R; Elbarbry, F | 1 |
| Douce, GR; Evans, TJ; McCaughey, LC; Ritchie, ND; Walker, D | 1 |
| Delaisi, B; Dominique, S; Hubert, D; Kho, P; Kovarik, JM; Leroy, S; Mely, L; Murris-Espin, M; Nove-Josserand, R | 1 |
| Bhatt, J; Smyth, AR | 1 |
| Coulthard, K; Doecke, C; Greville, H; Soulsby, N | 1 |
| Ducharme, MP; Lavigne, J; Marier, JF | 1 |
| Anbar, RD; Colin, AA; Lester, LA; Murphy, TD; Nasr, SZ; Nickerson, B; VanDevanter, DR | 1 |
| Bowman, CM | 1 |
| Gallagher, CG; Hodson, ME | 1 |
| Govan, JR | 1 |
| Coulthard, K; Lind, A; Madsen, V; Rasmussen, M | 1 |
| Lobue, PA | 1 |
| Scheinberg, P; Shore, E | 1 |
| Alvarez, A; Baquero, F; Cantón, R; Cobos, N; de Gracia, J; García-Quetglas, E; Gartner, S; Honorato, J; Oliver, A; Salcedo, A | 1 |
| Glass, S; Plant, ND; Spencer, DA | 1 |
| Atenafu, E; Bitnun, A; Dekker, A; Lam, W; Ratjen, F; Seto, W; Solomon, M; Tjon, J; Waters, V; Wong, C; Yau, Y | 1 |
| Armero Ibáñez, R; Lluch Oltra, A; Sifre Julio, C; Solaz Roldán, C | 1 |
| Goldmann, DA; Matthews, WJ; McLaughlin, FJ; Strieder, DJ; Sullivan, B | 1 |
| Batten, JC; Hodson, ME; Wingfield, HJ | 1 |
| Hoogkamp-Korstanje, JA; van der Laag, J | 1 |
| Blackwood, LL; Pennington, JE | 1 |
| Boat, TF; Cheng, PW; Powell, SH; Reed, MD; Stern, RC; Vermeulen, MW | 1 |
| Fan, L; Kelly, HB; Menendez, R; Murphy, S | 1 |
| Rampazzo, F; Serembe, M | 1 |
| Anderson, CM; George, RH; Healing, DE; Martin, AJ; Smalley, CA | 1 |
| Crimi, N; Ginesu, F; Grassi, C; Periti, P; Pozzi, E; Rimoldi, R | 1 |
| Barclay, ML; Begg, EJ; Chambers, ST; Grimwood, K; Pattemore, PK; Thornley, PE | 1 |
| Beaulac, C; Clément-Major, S; Hawari, J; Lagacé, J | 1 |
| Itokazu, GS; Weinstein, RA | 1 |
| Faris, M; O'Riordan, T | 1 |
| Beringer, PM | 1 |
| Beaulac, C; Lagacé, J; Sachetelli, S | 1 |
| Beringer, PM; Jelliffe, RW; Shapiro, BJ; Vinks, AA | 1 |
| Emerson, J; Montgomery, AB; Pepe, M; Ramsey, B; Rosenfeld, M; Smith, A; Williams-Warren, J | 1 |
| Döring, G; Nikolaizik, WH; Ratjen, F | 1 |
| Bender, SW; Knothe, H; Paporisz, U; Posselt, HG; Ristow, W; Röser, D; Wönne, R | 2 |
| Kulczycki, LL; Wientzen, R | 1 |
| Kroening, U; Liebig, S; Wundschock, M | 1 |
| Crozier, DN; Khan, SR | 1 |
| Neu, HC; Parry, MF | 1 |
| Baran, D; de Vuyst, P; Ooms, HA | 1 |
| De Boeck, K; Eggermont, E; Smet, M | 1 |
| Alekseeva, ME; Firsov, AA; Fomina, IP; Lukomskiĭ, GI; Manuĭlov, KK | 1 |
| Alhadeff, JA; Guman-Wignot, TM; Holsclaw, DS; Kaufman, J; Schmoyer, IR | 1 |
| Flensborg, EW; Høiby, N; Jensen, T; Koch, C; Pedersen, SS | 1 |
| Friis-Møller, A; Høiby, N; Koch, C; Pedersen, M; Pressler, T; Stenvang Pedersen, S | 1 |
| Black, PG; Bosso, JA; Matsen, JM | 1 |
| Rubio, TT | 1 |
| Davidson, S; Nakatomi, M; Neu, HC; Ores, C; Scully, BE | 1 |
| de Witte, J; Degener, JE; Driessen, O; Dzoljic-Danilovic, G; Hop, WC; Horrevorts, AM; Kerrebijn, KF; Michel, MF | 1 |
5 review(s) available for tobramycin and Lung Diseases
| Article | Year |
|---|---|
Inhaled antibiotics for the treatment of chronic bronchopulmonary Pseudomonas aeruginosa infection in cystic fibrosis: systematic review of randomised controlled trials.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Aztreonam; Chronic Disease; Colistin; Cystic Fibrosis; Humans; Lung Diseases; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2013 |
Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
Topics: Adolescent; Adult; Aminoglycosides; Anti-Bacterial Agents; Bacterial Infections; Child; Cystic Fibrosis; Drug Administration Schedule; Drug Therapy, Combination; Female; Forced Expiratory Volume; Humans; Injections, Intravenous; Lung Diseases; Male; Randomized Controlled Trials as Topic; Tobramycin; Vital Capacity | 2010 |
Antimicrobial therapy for pulmonary pathogenic colonisation and infection by Pseudomonas aeruginosa in cystic fibrosis patients.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Bronchopneumonia; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Inhalation; Injections, Intravenous; Lung Diseases; Pneumonia, Bacterial; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2005 |
Inhaled antimicrobial therapy.
Topics: Administration, Inhalation; Aerosols; AIDS-Related Opportunistic Infections; Anti-Bacterial Agents; Anti-Infective Agents; Antifungal Agents; Antiviral Agents; Bronchitis; Colony Count, Microbial; Cystic Fibrosis; Humans; Lung Diseases; Pentamidine; Pneumonia, Pneumocystis; Respiration, Artificial; Ribavirin; Sputum; Tobramycin; Tracheitis | 1999 |
New approaches to optimizing antimicrobial therapy in patients with cystic fibrosis.
Topics: Acute Disease; Administration, Inhalation; Aerosols; Airway Obstruction; Anti-Bacterial Agents; Anti-Inflammatory Agents; Chronic Disease; Cystic Fibrosis; Humans; Lung Diseases; Macrolides; Membrane Proteins; Nutritional Physiological Phenomena; Peptides; Tobramycin | 1999 |
14 trial(s) available for tobramycin and Lung Diseases
| Article | Year |
|---|---|
Pharmacokinetics and safety of tobramycin administered by the PARI eFlow rapid nebulizer in cystic fibrosis.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Cross-Over Studies; Cystic Fibrosis; Female; Humans; Lung; Lung Diseases; Male; Nebulizers and Vaporizers; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome; Young Adult | 2009 |
Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease.
Topics: Administration, Inhalation; Adolescent; Anti-Bacterial Agents; Child; Cough; Cystic Fibrosis; Female; Fever; Hospitalization; Humans; Lung Diseases; Male; Survival Analysis; Survival Rate; Time Factors; Tobramycin; Treatment Outcome | 2004 |
The long-term use of inhaled tobramycin in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Age Factors; Anti-Bacterial Agents; Child; Cystic Fibrosis; Double-Blind Method; Female; Humans; Lung Diseases; Male; Pseudomonas Infections; Time Factors; Tobramycin; Treatment Outcome | 2002 |
A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis.
Topics: Administration, Inhalation; Aged; Anti-Bacterial Agents; Bronchiectasis; Female; Humans; Lung Diseases; Male; Middle Aged; Pilot Projects; Pseudomonas Infections; Severity of Illness Index; Solutions; Tobramycin | 2005 |
Randomized, double-blind evaluation of azlocillin for the treatment of pulmonary exacerbations of cystic fibrosis.
Topics: Adolescent; Adult; Aged; Azlocillin; Bacterial Infections; Child; Clinical Trials as Topic; Cystic Fibrosis; Double-Blind Method; Drug Therapy, Combination; Humans; Lung Diseases; Middle Aged; Penicillins; Random Allocation; Respiratory Function Tests; Sputum; Ticarcillin; Tobramycin | 1983 |
Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis.
Topics: Adolescent; Child; Cystic Fibrosis; Drug Therapy, Combination; Humans; Lung Diseases; Piperacillin; Pseudomonas Infections; Tobramycin | 1983 |
Once-daily tobramycin therapy in lower respiratory tract infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Female; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Injections, Intramuscular; Injections, Intravenous; Italy; Lactams; Lung Diseases; Male; Middle Aged; Tobramycin; Treatment Outcome | 1995 |
Pharmacokinetics of tobramycin in adults with cystic fibrosis: implications for once-daily administration.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Area Under Curve; Bayes Theorem; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Models, Biological; Pseudomonas Infections; Tobramycin | 2000 |
Defining a pulmonary exacerbation in cystic fibrosis.
Topics: Administration, Inhalation; Adult; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Maximal Expiratory Flow Rate; Multicenter Studies as Topic; Randomized Controlled Trials as Topic; ROC Curve; Surveys and Questionnaires; Tobramycin | 2001 |
Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication.
Topics: Ceftazidime; Chronic Disease; Cystic Fibrosis; Drug Combinations; Forced Expiratory Volume; Humans; Leukocyte Count; Lung Diseases; Neutrophils; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Tobramycin; Vital Capacity | 1989 |
Immediate and prolonged clinical efficacy of ceftazidime versus ceftazidime plus tobramycin in chronic Pseudomonas aeruginosa infection in cystic fibrosis.
Topics: Adult; Ceftazidime; Child; Child, Preschool; Chronic Disease; Clinical Trials as Topic; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Lung Diseases; Male; Pseudomonas Infections; Random Allocation; Time Factors; Tobramycin | 1986 |
Ciprofloxacin versus tobramycin plus azlocillin in pulmonary exacerbations in adult patients with cystic fibrosis.
Topics: Adult; Anti-Bacterial Agents; Azlocillin; Bacterial Infections; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Therapy, Combination; Humans; Lung Diseases; Random Allocation; Therapeutic Equivalency; Tobramycin | 1987 |
Ciprofloxacin: comparative data in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Lung Diseases; Male; Penicillin Resistance; Pseudomonas Infections; Tobramycin | 1987 |
Ciprofloxacin therapy in cystic fibrosis.
Topics: Adolescent; Adult; Azlocillin; Child; Ciprofloxacin; Clinical Trials as Topic; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Lung Diseases; Male; Pseudomonas Infections; Tobramycin | 1987 |
40 other study(ies) available for tobramycin and Lung Diseases
| Article | Year |
|---|---|
Efficacy of aerosol MP-376, a levofloxacin inhalation solution, in models of mouse lung infection due to Pseudomonas aeruginosa.
Topics: Administration, Inhalation; Aerosols; Animals; Anti-Bacterial Agents; Aztreonam; Disease Models, Animal; Female; Levofloxacin; Lung Diseases; Mice; Microbial Sensitivity Tests; Ofloxacin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2009 |
In vitro pharmacodynamics of levofloxacin and other aerosolized antibiotics under multiple conditions relevant to chronic pulmonary infection in cystic fibrosis.
Topics: Aerosols; Anti-Bacterial Agents; Bacteria; Biofilms; Chronic Disease; Ciprofloxacin; Colony Count, Microbial; Cystic Fibrosis; Humans; Levofloxacin; Lung Diseases; Microbial Sensitivity Tests; Ofloxacin; Sputum | 2010 |
New co-spray-dried tobramycin nanoparticles-clarithromycin inhaled powder systems for lung infection therapy in cystic fibrosis patients.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Clarithromycin; Cystic Fibrosis; Desiccation; Drug Delivery Systems; Humans; Lung; Lung Diseases; Nanoparticles; Powders; Respiratory Tract Infections; Solubility; Tobramycin | 2013 |
Carrier-free combination for dry powder inhalation of antibiotics in the treatment of lung infections in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bacterial Infections; Clarithromycin; Crystallization; Cystic Fibrosis; Drug Combinations; Drug Compounding; Drug Synergism; Dry Powder Inhalers; Lung; Lung Diseases; Microscopy, Electron, Scanning; Particle Size; Powders; Tissue Distribution; Tobramycin; X-Ray Diffraction | 2013 |
Co-administration of aqueous ginseng extract with tobramycin stimulates the pro-inflammatory response and promotes the killing of Pseudomonas aeruginosa in the lungs of infected rats.
Topics: Agar; Animals; Anti-Bacterial Agents; Bacterial Load; Body Weight; Chemokines; Culture Media; Cytokines; Inflammation; Lung; Lung Diseases; Male; Organ Size; Panax; Plant Extracts; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Tobramycin | 2013 |
Physical Characterization of Tobramycin Inhalation Powder: I. Rational Design of a Stable Engineered-Particle Formulation for Delivery to the Lungs.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Drug Delivery Systems; Drug Stability; Dry Powder Inhalers; Humans; Lung Diseases; Nanoparticles; Particle Size; Powders; Tobramycin | 2015 |
In Vivo Efficacy of Antimicrobials against Biofilm-Producing Pseudomonas aeruginosa.
Topics: Animals; Anti-Infective Agents; Biofilms; Cell Line, Tumor; Colistin; Cystic Fibrosis; Disease Models, Animal; Female; Lung Diseases; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2015 |
Pharmacokinetics of once and twice daily dosing of intravenous tobramycin in paediatric patients with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Drug Administration Schedule; Female; Humans; Infant; Lung Diseases; Male; Retrospective Studies; Tobramycin | 2016 |
Efficacy of species-specific protein antibiotics in a murine model of acute Pseudomonas aeruginosa lung infection.
Topics: Animals; Anti-Bacterial Agents; Bacteriocins; Disease Models, Animal; Female; Lung; Lung Diseases; Mice; Mice, Inbred C57BL; Pseudomonas aeruginosa; Pseudomonas Infections; Pyocins; Species Specificity; Tobramycin | 2016 |
What is the best method for measuring renal function in adults and children with cystic fibrosis?
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Creatinine; Cystatin C; Cystic Fibrosis; Data Interpretation, Statistical; Female; Glomerular Filtration Rate; Humans; Infections; Injections, Intravenous; Kidney Function Tests; Lung Diseases; Male; Middle Aged; Radiopharmaceuticals; Sensitivity and Specificity; Technetium Tc 99m Pentetate; Tobramycin; Young Adult | 2010 |
Pharmacokinetics and efficacies of liposomal and conventional formulations of tobramycin after intratracheal administration in rats with pulmonary Burkholderia cepacia infection.
Topics: Animals; Burkholderia cepacia; Burkholderia Infections; Half-Life; Intubation, Intratracheal; Liposomes; Lung Diseases; Male; Rats; Rats, Sprague-Dawley; Tobramycin | 2002 |
New clinical evidence from the European tobramycin trial in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Colistin; Cystic Fibrosis; Europe; Humans; Lung Diseases; Nebulizers and Vaporizers; Pseudomonas Infections; Randomized Controlled Trials as Topic; Respiratory Function Tests; Tobramycin; Treatment Outcome | 2002 |
Insights into cystic fibrosis microbiology from the European tobramycin trial in cystic fibrosis.
Topics: Administration, Inhalation; Anti-Bacterial Agents; Biofilms; Colistin; Cystic Fibrosis; Europe; Humans; Lung Diseases; Microbial Sensitivity Tests; Nebulizers and Vaporizers; Pseudomonas Infections; Randomized Controlled Trials as Topic; Tobramycin | 2002 |
Determination of tobramycin in saliva is not suitable for therapeutic drug monitoring of patients with cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Child; Cystic Fibrosis; Dose-Response Relationship, Drug; Drug Monitoring; Female; Humans; Injections, Intravenous; Lung Diseases; Male; Nephelometry and Turbidimetry; Pseudomonas aeruginosa; Pseudomonas Infections; Saliva; Tobramycin | 2004 |
Inhaled tobramycin: not just for cystic fibrosis anymore?
Topics: Administration, Inhalation; Anti-Bacterial Agents; Bronchiectasis; Cystic Fibrosis; Humans; Lung Diseases; Pseudomonas Infections; Tobramycin | 2005 |
The effects of intravenous tobramycin on renal tubular function in children with cystic fibrosis.
Topics: Acetylglucosaminidase; Adolescent; Analysis of Variance; Anti-Bacterial Agents; Biomarkers; Child; Child, Preschool; Creatinine; Cystic Fibrosis; Female; Glomerular Filtration Rate; Humans; Infusions, Intravenous; Kidney Function Tests; Kidney Tubules, Proximal; Lung Diseases; Magnesium; Male; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Tobramycin; Treatment Outcome | 2005 |
Pharmacokinetic modelling of a once-daily dosing regimen for intravenous tobramycin in paediatric cystic fibrosis patients.
Topics: Adolescent; Anti-Bacterial Agents; Area Under Curve; Child; Computer Simulation; Cystic Fibrosis; Dose-Response Relationship, Drug; Female; Humans; Injections, Intravenous; Lung Diseases; Male; Models, Statistical; Nutritional Status; Pancreas; Retrospective Studies; Sample Size; Tobramycin | 2007 |
[Trobramycin by inhalation].
Topics: Administration, Inhalation; Adult; Aminoglycosides; Humans; Lung Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2008 |
Tobramycin and carbenicillin compared with gentamicin and carbenicillin in the treatment of infection with Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Carbenicillin; Cystic Fibrosis; Drug Therapy, Combination; Female; Gentamicins; Humans; Lung Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1983 |
Influence of mucoid coating on clearance of Pseudomonas aeruginosa from lungs.
Topics: Animals; Bacterial Vaccines; Guinea Pigs; Lipopolysaccharides; Lung Diseases; Polysaccharides, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1981 |
Are measurements of urine enzymes useful during aminoglycoside therapy?
Topics: Acetylglucosaminidase; Adolescent; Adult; alpha-L-Fucosidase; Aminoglycosides; beta-Galactosidase; Child; Child, Preschool; Cystic Fibrosis; Female; Gentamicins; Glycoside Hydrolases; Humans; Kidney; Lung Diseases; Male; Middle Aged; Muramidase; Pseudomonas Infections; Tobramycin | 1981 |
Pharmacokinetics of tobramycin in cystic fibrosis.
Topics: Adolescent; Adult; Aminoglycosides; Anti-Bacterial Agents; Biopharmaceutics; Body Surface Area; Body Weight; Child; Child, Preschool; Creatinine; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Pseudomonas Infections; Tobramycin | 1982 |
[Tobramycin in the treatment of non-tubercular infectious bronchopneumopathies].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bronchial Diseases; Female; Humans; Lung Abscess; Lung Diseases; Lung Neoplasms; Male; Middle Aged; Pleural Diseases; Tobramycin | 1981 |
Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis.
Topics: Adolescent; Anti-Bacterial Agents; Carbenicillin; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Gentamicins; Humans; Lung Diseases; Pseudomonas Infections; Tobramycin | 1980 |
Adaptive resistance to tobramycin in Pseudomonas aeruginosa lung infection in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Drug Resistance, Microbial; Female; Humans; Lung Diseases; Male; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Time Factors; Tobramycin | 1996 |
Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection.
Topics: Animals; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Chronic Disease; Colony Count, Microbial; Liposomes; Lung; Lung Diseases; Mucous Membrane; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Spectrophotometry, Ultraviolet; Tissue Distribution; Tobramycin | 1996 |
Aerosolized antimicrobials: another look.
Topics: Aerosols; Amikacin; Anti-Bacterial Agents; Bacterial Infections; Cytokines; Humans; Lung; Lung Diseases; Nebulizers and Vaporizers; Respiration, Artificial; Tobramycin; Ventilators, Mechanical | 1998 |
Aerosolization of low phase transition temperature liposomal tobramycin as a dry powder in an animal model of chronic pulmonary infection caused by Pseudomonas aeruginosa.
Topics: Aerosols; Animals; Anti-Bacterial Agents; Chronic Disease; Disease Models, Animal; Drug Carriers; Liposomes; Lung Diseases; Powders; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Temperature; Tobramycin | 1999 |
Effect of inhaled tobramycin on early Pseudomonas aeruginosa colonisation in patients with cystic fibrosis.
Topics: Administration, Inhalation; Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Cystic Fibrosis; Humans; Infant; Lung Diseases; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tobramycin | 2001 |
Evaluation of long term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Pseudomonas Infections; Radiography; Respiratory Function Tests; Time Factors; Tobramycin | 1979 |
The use and abuse of antibiotics, including in management of pulmonary manifestations in cystic fibrosis.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Humans; Lung Diseases; Substance-Related Disorders; Tobramycin | 1979 |
Long-term tobramycin therapy in patients with cystic fibrosis and advanced pulmonary disease.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Humans; Infant; Lung Diseases; Pseudomonas Infections; Time Factors; Tobramycin | 1979 |
[Tobramycin Concentration in Human Lung Tissue (author's transl)].
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Infections; Female; Humans; Lung; Lung Diseases; Male; Middle Aged; Muscles; Tobramycin | 1978 |
Tobramycin in treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Chronic Disease; Cystic Fibrosis; Female; Humans; Lung Diseases; Male; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1976 |
Tobramycin and ticarcillin therapy for exacerbations of pulmonary disease in patients with cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Lung Diseases; Male; Penicillins; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin; Tobramycin | 1976 |
Concentration of tobramycin given by aerosol in the fluid obtained by bronchoalveolar lavage.
Topics: Administration, Intranasal; Adult; Bronchoalveolar Lavage Fluid; Humans; Lung Diseases; Nebulizers and Vaporizers; Tobramycin | 1990 |
[Pharmacokinetic monitoring during aminoglycoside treatment: the optimal method for individualizing the dosage of tobramycin].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Humans; Lung Diseases; Middle Aged; Monitoring, Physiologic; Time Factors; Tobramycin | 1989 |
Analysis and HPLC fractionation of urine from patients with cystic fibrosis, chronic lung diseases and normal controls.
Topics: Adolescent; Adult; Biological Assay; Carbohydrates; Chemical Fractionation; Child; Chromatography, High Pressure Liquid; Chronic Disease; Creatinine; Cystic Fibrosis; Female; Humans; Hydrogen-Ion Concentration; Lung Diseases; Male; Proteinuria; Sialic Acids; Ticarcillin; Tobramycin | 1989 |
Management of Pseudomonas aeruginosa lung infection in Danish cystic fibrosis patients.
Topics: Adolescent; Anti-Bacterial Agents; Cystic Fibrosis; Denmark; Female; Follow-Up Studies; Humans; Lactams; Lung Diseases; Male; Pseudomonas Infections; Respiratory Function Tests; Tobramycin | 1987 |
Tobramycin in patients with cystic fibrosis. Adjustment in dosing interval for effective treatment.
Topics: Acute Disease; Adolescent; Adult; Child; Chronic Disease; Cystic Fibrosis; Drug Administration Schedule; Female; Forced Expiratory Volume; Humans; Lung Diseases; Male; Pseudomonas Infections; Tobramycin | 1987 |